首页> 美国卫生研究院文献>other >In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

【2h】

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

机译：HER2mRNA的原位定量测量可预测一组转移性乳腺癌患者受益于曲妥珠单抗化疗。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients.

机译：背景我们试图确定与传统方法相比在一组曲妥珠单抗治疗的转移性乳腺癌患者中原位mRNA测量的预测价值。

著录项

期刊名称 other
作者
Maria Vassilakopoulou; Taiwo Togun; Urania Dafni; Huan Cheng; Jennifer Bordeaux; Veronique M. Neumeister; Mattheos Bobos; George Pentheroudakis; Dimosthenis V. Skarlos; Dimitrios Pectasides; Vassiliki Kotoula; George Fountzilas; David L. Rimm; Amanda Psyrri;
展开▼
作者单位

展开▼
年(卷),期 -1(9),6
年度 -1
页码 e99131
总页数 8
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. [J] . Ono M, Ando M, Yunokawa M, International journal of clinical oncology . 2009,第1期

机译：接受曲妥珠单抗化疗的HER2过表达转移性乳腺癌患者的脑转移。
2. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer [J] . Makiko Ono, Masashi Ando, Mayu Yunokawa, International Journal of Clinical Oncology . 2009,第1期

机译：接受曲妥珠单抗化疗的HER2过表达转移性乳腺癌患者的脑转移
3. What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study [J] . Bakker J. L., Wever K., van Waesberghe J. H., Cancer epidemiology . 2015,第6期

机译：对于转移性乳腺癌患者，多线化疗有什么好处？回顾性队列研究
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Predicting chemotherapy resistance in breast cancer patients using radiofluorinated analogues of chemotherapy agents in conjunction with positron emission tomography. [D] . Kesner, Amanda Lovell. 2003

机译：结合使用化疗剂的放射性氟化类似物和正电子发射断层扫描术，可以预测乳腺癌患者的化疗耐药性。
6. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients [O] . YUNZHI WANG, THERESA THAI, KATHLEEN MOORE, -1

机译：使用CT图像定量测量肥胖症以预测基于贝伐单抗的化疗对上皮性卵巢癌患者的益处
7. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. [O] . Maria Vassilakopoulou, Taiwo Togun, Urania Dafni, 2014

机译：HER2mRNa的原位定量测量预测在一组转移性乳腺癌患者中从含曲妥珠单抗的化疗中获益。

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

摘要

著录项

相似文献

相关主题

期刊订阅